Sharyn Alfonsi reports on the unusual path fluvoxamine, a drug commonly used to treat obsessive-compulsive disorder, has had to becoming an early treatment candidate for COVID-19.

A cheap, generically available anti-depressant may reduce the risk of severe Covid-19 disease by close to a third in people at high risk, researchers reported Wednesday.

Higher-Dose Fluvoxamine Fails for COVID Outpatients — Recovery time with 100-mg dose no different than placebo by Ian Ingram , Managing Editor, MedPage Today November 17, 2023 • 3 min read ...

A safe, well-established antidepressant pill has proven effective at heading off severe COVID-19 cases, recent studies indicate. Fluvoxamine dramatically reduced the risk of hospitalization for ...

Participants were randomized in a 1:1 ratio to receive either fluvoxamine (50 mg twice daily on day 1, followed by 100 mg twice daily for 12 days) or placebo, ...

The new formulation will be available in 100-mg and 150-mg doses. Jazz Pharmaceuticals licensed the right to market this formulation from Solvay Pharmaceuticals in January 2007.